Premium Safinamide API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Safinamide / Safinamide Mesylate (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Selective Monoamine Oxidase B (MAO-B) Inhibitor

Indications: Parkinson's Disease (Adjunctive Therapy)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Safinamide distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Safinamide is an orally active, small-molecule Active Pharmaceutical Ingredient (API). Within central nervous system (CNS) pharmacology, it is classified as a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor.

For pharmaceutical formulators developing neurology portfolios, Safinamide presents a unique, dual mechanism of action. Primarily, it selectively inhibits the MAO-B enzyme, which is responsible for the degradation of dopamine in the brain. By blocking this pathway, Safinamide increases and sustains the extracellular levels of endogenous dopamine, as well as exogenous dopamine derived from levodopa treatments, in the striatum.

In addition to its dopaminergic mechanism, Safinamide acts on non-dopaminergic pathways. It functions as a state-dependent blocker of voltage-gated sodium channels and modulates the stimulated release of glutamate. This dual action is particularly critical in the management of Parkinson's disease, as it addresses both motor symptoms and the neural excitotoxicity associated with the disease progression.

For pharmaceutical manufacturing, integrating this API enables the production of critical adjunct therapies for Parkinson's patients experiencing "off" episodes while currently on a levodopa/carbidopa regimen. In commercial settings, this active ingredient is predominantly formulated as 50 mg and 100 mg immediate-release, film-coated oral tablets.

Sourcing Safinamide in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced CNS formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty neurological APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. As a dedicated pharmaceutical raw material supplier, sourcing Safinamide Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you are executing a pilot run or require a high-volume Safinamide api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during high-shear blending and tablet compression processes.

Technical Specifications for QA & R&D

The Safinamide API (supplied primarily as the stable mesylate salt) undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: (S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide methanesulfonate
• CAS Number: 202825-46-5 (Mesylate salt) / 133865-89-1 (Free base)
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C18H23FN2O5S (Mesylate form)
• Molecular Weight: 398.45 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Safinamide mesylate is freely soluble in water and specific aqueous buffers. Detailed solubility parameters and intrinsic dissolution rates are documented in the technical data sheet to assist your analytical R&D teams with pre-formulation profiling and excipient compatibility studies.

Manufacturing and Handling Guidelines for Formulators

Safinamide is a centrally acting pharmacological compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, strictly protected from excessive heat and ambient humidity) to prevent chemical degradation.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or powered air-purifying respirators (PAPR), chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure containment isolators to prevent the inhalation of airborne particulates.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.